final action
on 11 Dec 2023
Last Applicant/ Owned by
184 Collins Industrial Blvd, Suite A
Athens
GA
30601
Serial Number
97173248 filed on 15th Dec 2021
Registration Number
N/A
Correspondent Address
Devon E. White
Filing Basis
1. intent to use
2. intent to use current
Disclaimer
NO DATA
Research and development in the field of neural exosome-based therapeutics for the treatment of neurodegenerative diseases; Research and development in the field of neural exosome-based platforms to harness the inherent properties of neural exosomes for their therapeutic and delivery capabilities; Research and development in the field of neural exosomes to transport a wide range of cargos includinRead More
Research and development in the field of neural exosome-based therapeutics for the treatment of neurodegenerative diseases; Research and development in the field of neural exosome-based platforms to harness the inherent properties of neural exosomes for their therapeutic and delivery capabilities; Research and development in the field of neural exosomes to transport a wide range of cargos including nucleic acids and proteins to treat a wide range of Central Nervous System (CNS) diseases, inflammatory diseases of the brain, and other auto-immune diseases of the brain caused by destruction of myelin and neuronal injury/death; Research and development in the field of neural exosomes, namely, to engineer exosomes to carry various biologically active drug molecules, target specific cell types or cellular pathways, and enhance the value of existing drug modalities; Research and development in the field of neural exosome platforms to reduce pro-inflammatory t-cells, increase anti-inflammatory t-cells, increase anti-inflammatory macrophages, decrease pro-inflammatory microglia, decrease acute and chronic inflammation, protect axons and neurons, and restore neuronal and myelin integrity for the treatment of Central Nervous System (CNS) diseases, inflammatory diseases of the brain, and other auto-immune diseases of the brain caused by destruction of myelin and neuronal injury/death; Research and development in the field of neural exosome platforms to transport a wide range of cargos including nucleic acids and proteins to treat a wide range of Central Nervous System (CNS) diseases, inflammatory diseases of the brain, and other auto-immune diseases of the brain caused by destruction of myelin and neuronal injury/death; Research and development in the field of next-generation neural exosomes to enhance blood-brain barrier penetration and/or enhance the properties of cell-targeting exosomes
No 97173248
No Service Mark
No 031928.0010
No
No
No
No
No
No
No
No
Status Date | Action Taken |
---|---|
08th Mar 2024 | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED |
08th Mar 2024 | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED |
11th Dec 2023 | NON-FINAL ACTION WRITTEN |
11th Dec 2023 | NON-FINAL ACTION E-MAILED |
11th Dec 2023 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
13th Nov 2023 | ASSIGNED TO EXAMINER |
25th Apr 2023 | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED |
19th Oct 2022 | SUSPENSION LETTER WRITTEN |
19th Oct 2022 | LETTER OF SUSPENSION E-MAILED |
19th Oct 2022 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED |